Core Viewpoint - Gilead Sciences, Inc. (GILD) is set to report its fourth-quarter and full-year 2025 results on February 10, with consensus estimates for sales at $7.57 billion and earnings per share (EPS) at $1.83 [1][5] Financial Estimates - The earnings estimate for 2025 has decreased to $8.13 from $8.18 per share over the past 60 days, while the estimate for 2026 has increased to $8.60 from $8.56 [1] - The current earnings estimates for Q1 and Q2 are $1.83 and $1.90, respectively, with a trend showing a decrease of 3.17% for Q1 and an increase of 2.70% for Q2 over the past 60 days [2] Earnings Performance - GILD has a strong earnings surprise history, beating estimates in three of the last four quarters with an average surprise of 7.80%, including a 14.88% beat in the last reported quarter [2][3] Product Performance - Gilead's HIV franchise, particularly Biktarvy and Descovy, remains the primary growth driver, with Biktarvy accounting for over 52% of the U.S. treatment market [5][8] - The estimated sales for Biktarvy and Descovy are $3.8 billion and $703 million, respectively, with Yeztugo contributing $39 million in the third quarter [9][10] - The liver disease portfolio has seen increased sales, particularly for Livdelzi, while cell therapy sales are expected to decline due to competitive pressures [12][13] Market Position and Valuation - GILD's shares have increased by 49.2% over the past year, outperforming the industry growth of 31% [15] - The current price/earnings ratio for GILD is 16.85x forward earnings, higher than its historical mean of 11.17x but lower than the large-cap pharma industry average of 18.13x [18] Strategic Initiatives - Gilead is focusing on innovation within its HIV portfolio and has received positive data from phase III studies for new treatments [19][20] - The company is also pursuing strategic collaborations, including partnerships with Merck to enhance its product offerings [25]

Core Insights - AstraZeneca (AZN) is set to report its fourth-quarter and full-year 2025 results on February 10, with a consensus estimate for quarterly sales at $15.71 billion and earnings at $2.18 per share [1][8] Group 1: Sales Drivers - Key medicines, particularly cancer drugs Calquence, Lynparza, Tagrisso, and Imfinzi, along with diabetes medication Farxiga/Forxiga, are expected to significantly contribute to fourth-quarter sales, driven by strong demand [2][8] - The Zacks Consensus Estimates for the key drugs are as follows: Calquence at $916 million, Lynparza at $881 million, Tagrisso at $1.88 billion, Imfinzi at $1.67 billion, and Farxiga/Forxiga at $2.01 billion [2] Group 2: Additional Contributions - Other drugs, including asthma medication Fasenra, COPD treatment Breztri, and lupus drug Saphnelo, are also anticipated to support sales growth, with estimates for Symbicort and Fasenra at $696 million and $544 million, respectively [4] - Sales from AstraZeneca's Rare Disease drugs, particularly Ultomiris and Strensiq, have shown significant growth and are expected to continue this trend in the upcoming quarter [5] Group 3: Financial Performance and Costs - The company is expected to see a rise in core operating costs due to investments in recent product launches and increased expenses for new clinical studies [6] - AstraZeneca has a history of decent performance, beating earnings estimates in three of the last four quarters, with an average surprise of 3.81% [7] Group 4: Earnings Prediction - The current Earnings ESP for AstraZeneca stands at -4.59%, indicating that an earnings beat is not predicted this time [10][11] - The Most Accurate Estimate for earnings is $2.08 per share, while the Zacks Consensus Estimate remains at $2.18 [11]

Core Insights - Hasbro, Inc. (HAS) is set to report its fourth-quarter fiscal 2025 results on February 10, with expectations of earnings and revenues rising year over year [1][8] Earnings Estimates - The Zacks Consensus Estimate for earnings is 99 cents per share, reflecting a 115.2% increase from 46 cents reported a year ago [2] - Revenue estimates stand at $1.29 billion, indicating a 16.8% increase from the prior year's quarter [2] Factors Influencing Q4 Performance - The Wizards of the Coast segment, particularly MAGIC: The Gathering, is expected to have driven top-line performance, with strong demand during the holiday season supported by major releases [3] - Consumer Products are anticipated to have contributed significantly to revenues, aided by improved shipment flow and retailer restocking following earlier disruptions [4] - Pricing strategies and product mix, with many items priced under $20, helped sustain consumer demand without aggressive price increases [5] Revenue Predictions - Total Consumer Products revenues are projected to decline by 4% year over year to $716.2 million, while Wizards of the Coast & Digital Gaming revenues are expected to rise by 53.4% year over year to $520.2 million [6] Earnings Performance Drivers - Earnings growth is likely supported by operating leverage from higher revenues in the Wizards segment, particularly from MAGIC, which has high margins [7] - Incremental holiday sales are expected to flow efficiently through the income statement, aided by consistent royalty expenses and improved shipment leverage in Consumer Products [7] Earnings Beat Expectations - The model predicts an earnings beat for Hasbro, with an Earnings ESP of +16.50% and a Zacks Rank of 3 (Hold) [9]

Key Takeaways Masco to Report Q4 Earnings: Here's What Investors Must KnowPlumbing Products may support sales, aided by higher pricing and steady e-commerce and trade demand.Masco's margins face pressure from tariffs, commodity inflation and lower volumes despite mitigation efforts.Masco Corporation (MAS) is scheduled to report its fourth-quarter 2025 results on Feb. 10, before the opening bell.In the last reported quarter, the company’s adjusted earnings and net sales missed the Zacks Consensus Estimate by ...

Core Insights - Principal Financial Group, Inc. (PFG) is anticipated to show improvements in both revenue and earnings for the fourth quarter of 2025, with revenue expected to reach $4.11 billion, reflecting a 0.7% increase year-over-year [1] - The earnings consensus estimate is set at $2.23 per share, indicating a year-over-year increase of 14.9%, with a 0.4% upward revision in the past 60 days [2] Financial Performance Expectations - The fourth-quarter results are likely to demonstrate strong performance in PRT, solid underwriting results, and overall business growth [5] - Operating revenues are expected to rise due to increased premiums and fees in Retirement and Income Solutions, Principal Asset Management, and Benefits and Protection [5] - Investment Management is projected to benefit from higher management fee revenues due to increased average assets under management (AUM) and disciplined expense management [6] Investment Income and Market Performance - Investment income is expected to improve from higher average invested assets in fixed maturities and increased income from derivatives and alternative investments for U.S. operations [7] - Assets under management are likely to benefit from strong market performance and positive net cash flow [8] Expense Considerations - Expenses are anticipated to rise due to higher benefits, claims, and settlement expenses [8] Comparative Analysis - Other insurance stocks such as American International Group, Inc. (AIG) and Assurant, Inc. (AIZ) are also expected to show positive earnings trends, with AIG's earnings consensus at $1.89 per share (up 45.3% year-over-year) and AIZ's at $5.55 per share (up 15.8% year-over-year) [11][12]

Core Insights - Cardinal Health, Inc. (CAH) is set to report its second-quarter fiscal 2026 results on February 5, with expectations of strong revenue and earnings growth driven by its Pharmaceutical and Specialty Solutions segment [2][3][4]. Financial Performance Expectations - The Zacks Consensus Estimate for CAH's revenues in Q2 fiscal 2026 is $64.49 billion, reflecting a 16.7% increase from the previous year [3]. - The consensus estimate for EPS is $2.37, indicating a 22.8% rise compared to the same period last year [3]. Revenue Growth Drivers - Revenue growth is anticipated to be robust, primarily due to the Pharmaceutical and Specialty Solutions segment, which has seen increased utilization across various product categories [4]. - In the first quarter, this segment's revenues grew by 23%, with a significant contribution from GLP-1 therapies, and profits increased by 26% [5]. Segment Performance Insights - Contributions from MSO platforms and BioPharma Solutions are expected to remain significant, although COVID vaccine distribution may have weakened year-over-year [6]. - The Global Medical Products and Distribution segment is projected to show mixed performance, with tariff-related costs expected to rise, potentially impacting profit growth [7]. - The Other segment, including at-Home Solutions and Nuclear and Precision Health Solutions, is likely to continue its strong growth trajectory, benefiting from high demand and early synergies from acquisitions [8]. Market Position and Share Performance - Over the past six months, CAH's shares have increased by 35.6%, outperforming the industry average growth of 16.9% [12]. - Despite this, CAH's performance has lagged behind the Zacks Medical sector's 5% increase and the S&P 500's 12.2% gain during the same period [12]. Earnings Beat Prediction - The company's earnings model suggests a likely earnings beat, supported by a positive Earnings ESP of +0.46% and a Zacks Rank of 2 (Buy) [10][11].

Core Viewpoint - Plains All American Pipeline, L.P. (PAA) is anticipated to report a decline in both earnings and revenues for the fourth quarter of 2025, with earnings estimated at 42 cents per unit and revenues at $11.55 billion, reflecting a year-over-year revenue decline of 6.85% [1][2][6]. Earnings Estimates - Fourth-quarter earnings estimates have decreased by 17.65% over the past 60 days, with the bottom-line projection aligning with the previous year's quarter [2]. - The average earnings surprise for PAA over the last four quarters is 4.21%, with two earnings beats and two misses [3][4]. Earnings Prediction Model - The Zacks model does not predict an earnings beat for PAA this quarter, as the Earnings ESP is -6.11% and the Zacks Rank is 3 (Hold) [5][7]. Revenue and Cash Flow - PAA's expected Q4 revenues of $11.55 billion represent a 6.85% decline year-over-year, with the company relying heavily on fee-based, long-term contracts that provide stable cash flow [6][10]. - The acquisition of EPIC Crude Holdings is expected to positively impact fourth-quarter earnings due to long-term volume commitments from customers [11]. Financial Performance Metrics - PAA's trailing 12-month return on equity is 11.04%, which is below the industry average of 13.28%, indicating less effective utilization of shareholders' funds [12]. - PAA's current trailing 12-month EV/EBITDA is 10.78X, slightly undervalued compared to the industry average of 10.88X [14][15].

Core Insights - Wabtec Corporation (WAB) is set to report its fourth-quarter 2025 results on February 11, before market open [1] Earnings Estimates - The Zacks Consensus Estimate for WAB's fourth-quarter 2025 earnings has been revised upward by 0.49% to $2.07 per share, indicating a 23.2% increase from the previous year's actual earnings [2] - The consensus estimate for sales is currently $2.86 billion, suggesting a 10.6% increase from the year-ago figure [2] Performance History - Wabtec has a positive earnings surprise history, having outperformed the Zacks Consensus Estimate in three of the last four quarters, with an average earnings beat of 4.7% [3] Revenue Growth Factors - Wabtec's performance in the upcoming quarter is expected to be supported by an increase in total revenues, with Freight revenues estimated at $2 billion, reflecting an 11.7% growth year-over-year [4] - The Transit segment is projected to generate revenues of $853.65 million, indicating an 8.2% increase from the prior year, driven by strong aftermarket and original equipment manufacturing sales [4] Challenges - The company is likely facing pressure from rising operating expenses and ongoing supply-chain and tariff-related disruptions, which may negatively impact its bottom-line performance [5] Earnings Prediction Model - The current model does not predict a definitive earnings beat for Wabtec, as it has an Earnings ESP of -0.24% and a Zacks Rank of 2 (Buy) [6]

Core Insights - Arch Capital Group Ltd. (ACGL) is anticipated to show improvements in both revenue and earnings for the fourth quarter of 2025, with results expected to be reported on February 9 [1][2] Revenue and Earnings Estimates - The Zacks Consensus Estimate for ACGL's fourth-quarter revenues is $4.66 billion, reflecting a 2.3% increase from the previous year [1] - The consensus estimate for earnings is $2.49 per share, indicating a year-over-year rise of 10.1%, with a 6.4% upward revision in the past 30 days [2] Earnings Prediction Model - The earnings prediction model suggests a likely earnings beat for ACGL, supported by a positive Earnings ESP of +4.54% and a Zacks Rank of 3 (Hold) [3][4] Factors Influencing Q4 Results - Key factors expected to positively impact Q4 results include rate increases, new business opportunities, growth in existing accounts, product innovation, market expansion, and strong underwriting performance [5] - The Zacks Consensus Estimate for net premiums earned is $4.2 billion, with an expected increase of 2.2% [5][9] Investment Income and Expenses - Net investment income is projected to be $398.5 million, benefiting from solid cash flow from operating activities, although the Zacks Consensus Estimate for investment income is $417 million [6] - Total expenses are expected to rise by 2.9% to $3.7 billion due to higher losses, acquisition costs, and other operating expenses [7] Underwriting Profitability - Improved underwriting profitability is anticipated due to prudent underwriting practices, better pricing, and a less active catastrophe environment, with the combined ratio estimated at 84.5 compared to the Zacks Consensus Estimate of 83 [8][9]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Antero Resources despite higher revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Antero Resources is expected to report quarterly earnings of $0.53 per share, reflecting an 8.6% decrease year-over-year [3]. - Revenue projections stand at $1.31 billion, indicating a 12% increase from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 23.96% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, with positive readings being more reliable [9][10]. - Antero Resources currently holds a Zacks Rank of 3, complicating predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, Antero Resources was expected to earn $0.22 per share but only achieved $0.15, resulting in a -31.82% surprise [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Conclusion - Antero Resources does not appear to be a strong candidate for an earnings beat, and investors should consider additional factors when making decisions regarding the stock ahead of the earnings release [17].